Search
Sagimet Biosciences Inc
SGMTAdd to Watchlist
7.610USD
+0.150+2.01%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
247.49MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.01%
5 Days
+7.79%
1 Month
+7.79%
6 Months
+27.05%
Year to Date
+28.55%
1 Year
-7.76%
Key Figures
7.540Open
7.690High
834.22KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.57%Turnover Ratio
7.460Prev. Close
7.410Low
4.23MTurnover
LossP/E Static
2.08P/B
0.00%Div Yield TTM
-34.27%ROA
11.41052wk High
0.54Volume Ratio
-45.57MNet Profit
32.52MShares
-1.3404EPS TTM
--Beta
-36.04%ROE
3.32052wk Low
3.75%Amplitude
100.00%Gross Margin
247.49MMarket Cap
1.25Reward/Risk
4.55%Risk Rate
TradingKey Stock Score of Sagimet Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Sagimet Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 92 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.36.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sagimet Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Sagimet Biosciences Inc Highlights
StrengthsRisks
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -5.68, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.88M shares, decreasing 24.92% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 135.74K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.34.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
26.364
Target Price
+253.40%
Upside Space
Sagimet Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sagimet Biosciences Inc Info
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Ticker SymbolSGMT
CompanySagimet Biosciences Inc
CEOHappel (David)
Websitehttps://sagimet.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Sagimet Biosciences Inc (SGMT)?
The current price of Sagimet Biosciences Inc (SGMT) is 7.61.
What is the symbol of Sagimet Biosciences Inc?
The ticker symbol of Sagimet Biosciences Inc is SGMT.
What is the 52-week high of Sagimet Biosciences Inc?
The 52-week high of Sagimet Biosciences Inc is 11.41.
What is the 52-week low of Sagimet Biosciences Inc?
The 52-week low of Sagimet Biosciences Inc is 3.32.
What is the market capitalization of Sagimet Biosciences Inc?
The market capitalization of Sagimet Biosciences Inc is 247.49M.
Is Sagimet Biosciences Inc (SGMT) currently rated as Buy, Hold, or Sell?
According to analysts, Sagimet Biosciences Inc (SGMT) has an overall rating of Buy, with a price target of 26.36.
What is the Earnings Per Share (EPS TTM) of Sagimet Biosciences Inc (SGMT)?
The Earnings Per Share (EPS TTM) of Sagimet Biosciences Inc (SGMT) is -1.58.